Plain-English translation of NCT05842707 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment called dualCAR-NK19/70, which uses immune cells from donated umbilical cord blood that have been engineered in a laboratory to recognize and attack lymphoma cells. The medication is designed for people whose B-cell lymphoma has come back or stopped responding to previous treatments. Researchers want to find the safest and most effective dose of this new treatment.
Many people with aggressive lymphomas eventually stop responding to standard chemotherapy and immunotherapy, leaving them with limited options. This trial exists to see whether this new engineered cell treatment can help patients whose cancer has become resistant to other therapies.
You likely qualify if…
You likely don't qualify if…
The trial has two parts. In the first part, small groups of patients receive increasing doses of the engineered cells to find the safest level. In the second part, more patients receive the dose that worked best from part one. You will receive the cells as an infusion and be closely monitored for safety, side effects, and how well the treatment is working through blood tests, imaging scans, and regular clinic visits over many months.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China